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Abstract: During the recent years, immune checkpoint-based therapy has proven highly 
effective in microsatellite instable (MSI) solid tumors irrespective of organ site. MSI tumors 
are associated with a defective mismatch repair (MMR) system and a highly immune- 
infiltrative tumor microenvironment—both characteristics of Lynch syndrome. Lynch syn-
drome is a multi-tumor syndrome that not only confers a high risk of colorectal and 
endometrial cancer but also cancer in, eg the upper urinary tract, ovaries, and small bowel. 
Since the genetic predisposition for Lynch syndrome are pathogenic variants in one of the 
four MMR genes, MLH1, MSH2, MSH6 or PMS2, most of the Lynch syndrome cancers show 
MMR deficiency, MSI, and activation of the immune response system. Hence, Lynch 
syndrome cancer patients may be optimal candidates for immune checkpoint-based therapies. 
However, molecular differences have been described between sporadic MSI tumors (devel-
oped due to MLH1 promoter hypermethylation) and Lynch syndrome tumors, which may 
result in different treatment responses. Furthermore, the response profile of the rare Lynch 
syndrome cases may be masked by the more frequent cases of sporadic MSI tumors in large 
clinical trials. With this review, we systematically collected response data on Lynch syn-
drome patients treated with FDA- and EMA-approved immune checkpoint-based drugs 
(pembrolizumab, atezolizumab, durvalumab, avelumab, ipilimumab, and nivolumab) to 
elucidate the objective response rate and progression-free survival of cancer in Lynch 
syndrome patients. Herein, we report Lynch syndrome-related objective response rates 
between 46 and 71% for colorectal cancer and 14–100% for noncolorectal cancer in 
unselected cohorts as well as an overview of the Lynch syndrome case reports. To date, no 
difference in the response rates has been reported between Lynch syndrome and sporadic 
MSI cancer patients. 
Keywords: hereditary colorectal cancer, HNPCC, Lynch syndrome, endometrial cancer, 
germline mismatch repair defect
Introduction
Lynch syndrome, caused by germline pathogenic variants in the mismatch repair 
(MMR) genes, MLH1, PMS2, MSH2, and MSH6, is the most common type of 
hereditary colorectal cancer. The syndrome is, however, also associated with 
a series of other cancer types, including endometrial cancer, ovarian cancer, urothe-
lial tract cancer, small bowel cancer, gastric cancer, brain tumor, and sebaceous skin 
tumor.1–3 Lynch syndrome-associated tumors develop through inactivation of 
the second MMR allele leading to biallelic loss of MMR protein expression and 
hence deficient MMR (dMMR). Tumors with d-MMR have lost the ability to repair 
DNA errors introduced during replication and these tumors often present with high 
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levels of mutation, reflected as microsatellite instability 
(MSI).4 The increased number of mutations are often pre-
sented as neoantigens that recruit and activate the host 
immune cells.5 Further tumor progression can be facili-
tated through immunoediting like T cell exhaustion, eg, by 
targeting immune checkpoints like the programmed death 
1 (PD-1) or cytotoxic T lymphocyte antigen 4 (CTLA-4) 
receptors.6 Inhibiting these checkpoint blockades may 
reactivate the anti-tumorigenic T cells.
In 2017, MSI or dMMR were approved as pan-cancer 
biomarkers for the anti-PD-1 checkpoint therapy pembro-
lizumab by the American Food and Drug Administration 
(FDA).7 The approval was based on multicenter, multi-
cohort, single-arm trials, some of which included Lynch 
syndrome data.4,8 Shortly after, nivolumab was approved 
by the FDA in 2017 for MSI colorectal cancer and in 2018 
in combination with ipilimumab based on the CheckMate- 
142 study.7,8 Pembrolizumab has not received a tissue- 
agnostic indication by the European Medicines Agency 
(EMA) and despite comparable mechanism of action, the 
other immune checkpoint inhibitors, like atezolizumab, 
durvalumab, and avelumab, have neither been approved 
by the FDA nor the EMA in an MSI/dMMR pan-cancer 
setting.
Based on the expected tumor-agnostic effects, many 
Lynch syndrome MSI tumors may have been enrolled in 
clinical trials using these drugs. However, Lynch syn-
drome may only be the causative reason for tumor devel-
opment in a smaller subset of all MSI tumors (3–5%),9–12 
hence, their specific response rate may be masked by the 
responses of sporadic MSI cancers, that may differ mole-
cularly from Lynch syndrome tumors.13–16 Here, we 
review large clinical trials that have presented data sepa-
rately for Lynch syndrome and sporadic MSI cancer 
patients to elucidate the clinical benefit from immune 
checkpoint-based therapy in Lynch syndrome. 
Furthermore, we summarize current data on Lynch syn-




A systematic literature search was performed to identify 
studies with Lynch syndrome specific treatment data to 
evaluate the clinical benefit of immune checkpoint-based 
therapies in this cohort. All published studies including 
patients with Lynch syndrome-associated cancer, who had 
been treated with one or more of the FDA- and EMA- 
approved checkpoint-based immunotherapies targeting 
CTLA-4 (ipilimumab), PD-1 (pembrolizumab and nivolu-
mab), or PD-L1 (atezolizumab, avelumab, and durvalu-
mab) and where data was available on clinical outcomes, 
were considered eligible for this review.
The search strategy was developed in collaboration 
with a research librarian at the Medical Library, Aalborg 
University Hospital, Denmark. The search string was 
assembled from MeSH and non-MeSH terms included in 
the two categories: a cancer subtype specific domain 
[“Lynch syndrome” OR “hereditary MSI” OR “hereditary 
MMR-deficiency” OR “colorectal neoplasm, hereditary 
nonpolyposis”] and a treatment domain [“Ipilimumab” 
OR “Nivolumab” OR “Atezolizumab” OR “Durvalumab” 
OR “Pembrolizumab” OR “Avelumab”] combined with 
a Boolean logical “AND”. In PubMed, all search terms 
were coined as MESH terms, as SUPPLEMENTARY 
CONCEPT, or as TEXT WORD (combined with “OR”) 
securing capture of yet unindexed articles. In Embase, the 
search terms were used as EMTREE terms and TEXT 
WORDS. In Web of Science, the search terms were used 
as TOPIC. In the Cochrane Library, the search terms were 
used as MeSH terms and as Title, abstract, and keywords 
terms. No constraints related to language or publication 
type were applied—except for exclusion of conference 
abstracts on Embase. Detailed search terms are available 
from the authors upon request.
The final search in the four databases was conducted 
on November 3, 2020. The combined results of the analog 
searches in PubMed, Embase, Web of Science, and 
Cochrane Library were imported into the Rayyan QCRI 
application (Qatar Computing Research Institute, https:// 
libraryguides.mcgill.ca/rayyan, last updated on October 7, 
2020).17 Herein, all the items identified from the four 
databases were imported and the software identified 196 
duplicates, which were manually checked before removal 
(N=195). Studies identified through reference lists from 
the included studies (N=3)8,18,19 were included if they 
were scored as relevant (Figure 1).
Data Extraction
All studies identified were independently reviewed by four 
authors (IB, LHJ, MR, or CT) with at least two reviewers 
per item analyzing inclusion/exclusion criteria defining the 
study population. Whenever discrepancy was met, consen-
sus was reached involving a third reviewer.
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Study eligibility was performed following the preferred 
reporting items for systematic reviews and meta-analyses 
(PRISMA), while data extraction was performed using 
modified criteria based on the guidelines given by the 
Cochrane Collaboration.20 Data were extracted regarding 
study population (eg, age, sex, race, and MMR germline 
mutation), tumor type (eg, location, organ, dMMR/MSI 
status, and stage), treatment regimen (eg, pharmaceutical 
drug used, line of treatment, combinational treatment, and 
period), and outcome (eg, objective response rate, overall 
survival, progression-free survival, and alternative 
endpoints).
Since this was a scoping review, quality assessment 
was not conducted. Publication bias was considered, as 
case reports may only be reported when interesting 
results are available. Likewise, funding sources were 
extracted to assess any conflicts of interest. All studies 
were requested to be on Homo sapiens and written in 
Figure 1 Flowchart showing the systematic literature search and screening procedure following the preferred reporting items for systematic reviews and meta-analyses 
(PRISMA). Data extraction was performed using modified criteria based on the guidelines given by the Cochrane Collaboration for the 31 studies included.
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English and published as original articles unless suffi-
cient data could be extracted from an English abstract 
(N=1).21 Redundant data, which was published in over-
lapping studies, motivated exclusion (N=2) or merging 
of the studies (N=4) (Figure 1).18,22–24 When informa-
tion on overlapping data was missing, data from the two 
studies was presented separately according to the out-
come in focus.19,25 One study included two cases with 
two different tumor types and responses and was for 
clarity depicted as two separate case reports in Table 2.26
As this review included all types of MSI or dMMR 
Lynch syndrome-associated cancers (irrespective of organ 
or tumor stage) with all lines of therapy, and primarily case 
reports, meta-analysis was not considered appropriate. 
Instead, data was grouped by study design with clinical 
trials in unselected MSI/dMMR cancer cohorts scored as 
a high level of evidence, while case reports were consid-
ered to have a lower level of evidence and a higher level of 
bias.
Definitions
Lynch syndrome diagnostics were based on individuals 
with pathogenic or likely pathogenic variants in one of 
the four MMR genes: MLH1, PMS2, MSH2/EPCAM, 
and MSH6 found by germline DNA sequencing (18 
case studies and three cohort studies). Since some of 
the cohort studies included few variants of unknown 
significance (VUS) as causative for Lynch syndrome25 
or included Lynch syndrome families based on indivi-
duals with dMMR/MSI tumors in families with 
a cancer history,8,21 we chose to include two case 
studies with VUS26,27 and two case studies with clin-
ical Lynch syndrome diagnostics, but with unknown 
germline MMR gene variant.28,29 Lynch syndrome 
individuals with biallelic MMR variants (also referred 
to as constitutional MMR deficiency (CMMR-D) syn-
drome) were also included in this study, since these 
tumors show the same molecular phenotype as mono-
allelic Lynch syndrome tumors (N=1). There were no 
selection criteria regarding tumor type and no restric-
tions in period.
Outcome Data
The primary endpoints were objective response rate 
(ORR), progression-free survival (PFS), and overall sur-
vival (OS). ORR was measured as the best response 
during treatment or alternating immune checkpoint- 
based therapies using the response evaluation criteria 
in solid tumors (RECIST) guidelines, with partial 
response (PR) and complete response (CR) categorized 
as response. In cases where the RECIST criteria were 
not used, pathological complete response was classified 
as CR, while nonqualified tumor decrease was categor-
ized as stable disease (SD). Disease control rates were 
calculated as all CR, PR and SD divided by the total 
number of treated and evaluable patients. PFS was mea-
sured in months from first dose of immune checkpoint- 
based therapy to tumor progression or end of follow-up. 
In case of alternating immunotherapeutic regimens, PFS 
were defined as the time from first dose of immunother-
apy to end of the last regimen of immunotherapy caused 
by disease progression. OS was measured in months 
from the first dose of immune checkpoint-based therapy 
to death or end of follow-up. Inclusion of alternative 
endpoints was motivated when ORR data was not avail-
able, as these may translate into a clinically meaningful 
benefit in PFS and OS. Decreasing prostate specific 
antigen (PSA) level was categorized as disease control 
for one case according to the prostate cancer clinical 
trial working group (PCWG3) guideline.30 Whenever 
possible, the analyses were based on original raw data 
and Lynch syndrome cases were sought and extracted 




In total, 492 studies were identified (two from 
Cochrane Library, 167 from Embase, 130 from 
PubMed, and 193 from Web of Science) (Figure 1). 
After removal of 195 duplicates, 297 studies were 
reviewed on title and abstract level following the 
PRISMA guidelines. Hereafter, 47 studies were 
screened on full text level and three additional studies 
were added to the search based on the references of the 
reviewed publications.8,18,19 In total, 31 articles were 
included for this review, six of which included over-
lapping cases: two cases were described in two case 
reports18,22–24 and one clinical trial was updated with 
different data presented in two papers.19,25
Cohort Studies
Colorectal Cancer
Large cohort studies of consecutive unselected patients 
were considered to be less biased by publication and 
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were initially investigated for specific data on Lynch 
syndrome cases. Seven studies were identified and pre-
sented in Table 1. Three studies investigated the 
response rates in colorectal cancer and found that 
Lynch syndrome patients had an ORR between 46 
and 71% after immune checkpoint-based therapy.8,19 
Two of the articles presented data from the MK-3475 
study covering three to six centers in the 
US (NCT01876511), in which Lynch syndrome- 
associated ORR were calculated in the study from Le 
et al,25 while individual Lynch syndrome cases could 
be extracted in the study from Le et al.19,25 In Le 
et al,19 eight Lynch syndrome patients with colorectal 
cancer were treated with pembrolizumab, of which two 
showed PR giving an ORR of 25% and six showed SD 
reaching disease control in 100% of the patients. In the 
updated paper from 2017, the Lynch syndrome- 
associated ORR had increased to 46%.25 The percen-
tage of Lynch syndrome cases presenting with disease 
control was not specified in here, but 23% of the entire 
cohort (covering 86 patients) showed SD reaching dis-
ease control in 77% of the unselected MSI/dMMR 
cohort. Furthermore, mean time to response was 21 
weeks and mean time for complete response was 42 
weeks.25 Corresponding data from the sporadic MSI/ 
dMMR cohort were only specified in the paper from 
2015 with two colorectal cancer patients both showing 
PR (ORR=100%).19 Though similar data was missing 
in the updated paper from 201725 statistical analyses 
did not identify significant difference in ORR between 
Lynch syndrome and sporadic MSI/dMMR colorectal 
cancers (ORR of the entire study cohort was 52%). The 
CheckMate-142 study presented by Overman et al, 
which is a multicenter study covering 28 centers in 
eight countries, included 35 Lynch syndrome patients 
of which 25 patients showed objective response 
(ORR=71%).8 In comparison, sporadic (non-Lynch 
syndrome) MSI/dMMR colorectal cancers showed an 
ORR of 48%. No comparison was made between the 
two groups and lack of individual data restrained 
further analyses. For both clinical trials, sufficient fol-
low-up to calculate PFS and OS was not reached, and 
not specified for Lynch syndrome and sporadic MSI 
cancers individually.
Noncolorectal Cancer
Investigating noncolorectal cancers, we found four stu-
dies with specified Lynch syndrome response data, three 
of which published from the Memorial Sloan Kettering 
Cancer Center, New York, USA.21,31–33 Hu et al identi-
fied five Lynch syndrome patients in a retrospective 
cohort of 833 consecutively collected patients with pan-
creatic ductal carcinomas, of which three responded 
(ORR=60%) to anti-PD1/anti-PD-L1 drugs—one with 
a mixed response involving a complete response fol-
lowed by metastasis eight months later.33 The mean 
PFS of four cases with available data was 12.5 months, 
although the responses appeared after 22 and 24 months. 
No sporadic cases with an MSI phenotype were identi-
fied nor treated with immunotherapy. Abida et al, 2019 
identified two Lynch syndrome patients among 
a prospectively collected cohort of 1033 patients with 
prostate cancer, of which one showed PR and the other 
had PD after anti-PD-1/anti-PD-L1 therapy.31 Likewise, 
Raj et al found two Lynch syndrome patients in 
a prospective phase II study of 39 patients with adreno-
cortical carcinomas; both showed PR and a mean PFS of 
27.5 months when treated with pembrolizumab.32 In 
2015, the MK-3475 study from Johns Hopkins 
University presented three Lynch syndrome-associated 
noncolorectal cancer patients with an ORR of 33%.19 
In the updated cohort from 2017, this increased to 
59%.25
At the American Society of Clinical Oncology 
(ASCO) in May 2020, Bari et al, presented a large 
retrospective study design, in which they aimed to 
describe the response rates in a Lynch syndrome cohort 
irrespective of tumor type.21 They identified 194 Lynch 
syndrome patients with different types of solid tumors, 
of which 22 had received treatment with immune 
checkpoint-based therapies. Of the 22 patients, two 
showed CR, one had PR, 13 had SD, and six showed 
PD giving an ORR of 14% and a disease control rate of 
73%. In contrast to the other studies, treatment 
responses were measured irrespective of MSI status 
and showed continued response after nine months of 
treatment in one (out of three) microsatellite stable 
(MSS) Lynch syndrome tumors.21 Detailed PFS and 
OS were not calculated but 15 out of 22 patients 
showed continuous disease control or complete remis-
sion at 48 months of follow-up.
In summary, these studies identified 107 Lynch syn-
drome cancer patients and individual response data 
could be collected from 77 cases (excluding Le et al).25 
Thirty-six of these cases responded to treatment, giving 
a summarized ORR of 47% (63% for CRC and 29% for 
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noncolorectal cancer). In comparison, summarized ORR 
for sporadic MSI colorectal cancer patients were 55% 
(17 out of 33) and 42% for sporadic MSI noncolorectal 
cancer patients (five out of 12). PFS was only reported 
in three studies (all regarding noncolorectal cancers) and 




Next, we reviewed the Lynch syndrome cancer case 
reports. Twenty-four case reports covering 26 patients 
(three with multiple cancers) presented treatment 
response. Two cases were presented in two papers 
each, but since data was overlapping the studies were 
merged to two case reports.18,22–24 In contrast, one 
study presented to cases with two different types of 
MSI cancers and was for simplicity presented as two 
separate cases (Table 2).26 Cancer center, country, 
MMR gene affected, immune checkpoint-based treat-
ment, therapeutic setting, and outcome results for the 
26 unique cases are presented in Table 2. Two of the 
studies did not present data on the MMR gene test 
analyses nor the MMR variant identified in the 
patients, and it remains uncertain how Lynch syndrome 
was diagnosed in these individuals.28,29 The cases were 
identified in USA (N=13), Canada (N=3), China (N=3), 
Japan (N=2), France (N=1), Chile (N=1), UK (N=1), 
Brazil (N=1), and Australia (N=1). The responses were 
evaluated using the RECIST criteria (N=13), pathologic 
complete response with no viable tumor cells after 
surgery (N=2), tumor decrease with unknown percen-
tage of decrease (N=7), clinical response with pro-
ceeded treatment due to no or little tumor progression 
(N=2), and as a decrease in prostate specific antigen 
(PSA) (N=2).
The case reports either presented cases with clinical 
responses/disease control (N=21), or disease progression 
(N=4), or cases with two primary tumors, of which one 
progressed and the other responded (N=1). The majority of 
studies presenting positive treatment responses may indi-
cate publication bias as these cases are more likely to be 
published.
Colorectal Cancer
In summary, 10 cases were included with a colorectal 
cancer (three with multiple cancers in other organs as 
well) and one patient with liver metastases from 
a previously removed colorectal cancer.18,24,26,28,29,34–38 
Two cases obtained CR, two showed PR, three had SD, 
and three showed PD giving an ORR of 40% and dis-
ease control rate of 70%. All the patients, who showed 
positive response, were given immunotherapy as first 
(N=3) or second (N=1) line treatment. The mean PFS 
was 14.9 months with a mean time to response of 13.3 
months. As only one patient died one month after treat-
ment end,18,24 PFS was equal to OS in these cases.
Noncolorectal Cancer
Investigating noncolorectal cancers, 21 MSI/dMMR Lynch 
syndrome-associated solid tumors developed (three glio-
blastoma multiforme, four pancreatic cancers, three uret-
eral cancers, two lung cancers, two prostate cancers, two 
adrenocortical carcinomas, two bladder cancers, one endo-
metrial cancer, one rhabdomyosarcoma, and one intrahe-
patic cholangiocarcinoma).18,22–24,26,34,38–49 Although it 
was not stated, it was considered highly likely that the 
pancreatic cancer showing PD at 22 months by Hu et al,49 
was included in the large pancreatic cancer cohort 
study.33,49 However, in order to reduce publication bias, 
this case was included in the following summary. Among 
the 21 noncolorectal cancers, three showed CR, eight 
showed PR, eight had SD (two of which had decreased 
PSA levels as the only response data), and two experi-
enced PD resulting in a summarized ORR of 53% and 
disease control in 90%. Mean PFS was 14.1 months with 
a mean time to positive response of 18.3 months. Again, 
OS was not reported for the majority of the studies as 
follow-up was ended at tumor progression or with PFS.
Multiple Lines of Immunotherapy
Irrespective of the cancer type, treatment lines of which 
the immune checkpoint-based therapy was introduced 
varied across the included studies with seven tumors 
receiving immunotherapy in first line, 14 in second 
line, seven in third line, and three in fourth line. Two 
cases received different regimens of immunotherapy due 
to local progression or adverse events with the selected 
treatment. A male 64-year-old Lynch syndrome carrier 
presenting with three urothelial cancers (bladder and 
bilateral ureter) and a liver metastasis 10 years after 
previously removed colorectal cancer was treated with 
pembrolizumab at the indication of dMMR in one of the 
urothelial tumors. At nine months, the patient was trea-
ted with atezolizumab based on progression of the 
urothelial cancers. The patient obtained eight months 
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of disease control before progression of the liver metas-
tasis. Pembrolizumab was reintroduced for three months 
until progression and the patient switched to combina-
tion therapy with nivolumab and ipilimumab resulting in 
tumor decrease after two months. The patient continued 
therapy with nivolumab alone with disease control for 
seven months. At this time, his bilirubin levels increased 
probably attributed to immunotherapy-related adverse 
events and the patient declined continued therapy and 
passed away one month later.18,24
The second case report presented a boy at 3.5 years 
with homozygous biallelic PMS2 pathogenic variants with 
a glioblastoma multiforme tumor in the frontal cortex that 
was surgically removed. Ten months later multinodular 
recurrence was observed, and he was treated with nivolu-
mab with initial response. Six months later, a new nodal 
glioblastoma reoccurred at the primary surgical site and 
ipilimumab was added to the nivolumab treatment for four 
doses. Significant response was observed after three 
months (nine months from first immunotherapy dose) 
and complete response was reached after one year. The 
patient continued on nivolumab for maintenance and mag-
netic resonance imaging confirmed CR 30 months from 
first glioblastoma recurrence and first immunotherapeutic 
dose.
Discussion
Herein, we summarized the clinical responses among 
Lynch syndrome cancer patients treated with FDA- and 
EMA-approved checkpoint-based immune therapies. We 
identified 31 studies including 133 unique Lynch syn-
drome cancer patients. For Lynch syndrome, the large 
cohort studies showed ORRs between 46–71% for MSI/ 
dMMR colorectal cancers and 14–100% for noncolor-
ectal MSI/dMMR cancers. The corresponding ORRs for 
sporadic MSI/dMMR cancers were 48–100% and 
50–100%, respectively. Summarizing the Lynch syn-
drome case reports, the ORRs were 40% and 53%, 
respectively. In addition, the only study investigating 
a systematic difference between Lynch syndrome and 
sporadic MSI cancers did not reach any significance. 
Together the data indicates that Lynch syndrome cancer 
patients may benefit from immune checkpoint-based 
therapy to the same extend as sporadic MSI/dMMR 
tumors, though the sample size is limited and confidence 
intervals large.
Since the approval of pembrolizumab as a tissue- 
agnostic drug against MSI/dMMR solid tumors, more 
than 100 clinical trials have been registered at 
ClinicalTrial.gov and are still ongoing, testing immu-
notherapy in a wide range of solid tumors. Many of 
these studies select tumors based on MSI or dMMR 
status, but only a few studies choose to investigate 
hereditary germline MMR variants and even fewer to 
report the outcome data according to germline MMR 
status. One of the pioneering studies within this field 
is Le et al, who showed that Lynch syndrome cancer 
patients had an ORR of 27% compared to an ORR of 
100% for sporadic MSI tumors.19 The reduced response 
rate observed in these preliminary results is hypotheti-
cally supported by molecular differences between the 
sporadic and hereditary MSI tumors, including different 
immune evasion mechanism affecting, eg, the antigen 
processing and presentation pathway.14–16 However, the 
updated study from Le et al,25 reported no significant 
difference in response rates between the two subsets 
though separate ORRs for sporadic or Lynch syndrome 
MSI/dMMR tumors are not reported. The PFS and OS 
measures are still not complete and separate data for 
these groups is awaited.
Although many of the immune-checkpoint-based 
drugs are not approved for MSI/dMMR noncolorectal 
solid tumors, the case reports and cohort studies pre-
sented in here show that Lynch syndrome cancer 
patients may be potential candidates for such treatments. 
Complete responses (five out of 26 cases) were reported 
in advanced rectal cancer, glioblastoma, muscle invasive 
bladder cancer, and cases with lung metastases, albeit 
these stories may be more likely to get published than 
negative findings.22,43,45 It remains very important to 
publish Lynch syndrome cancer cases with resistance 
or tumor progression in response to immune checkpoint- 
based therapy as these tumors may evade the immune 
system through alternative routes. One such case was 
presented by Hu et al,49 in which mutation analyses was 
conducted on the primary pancreatic cancer and the 
ovarian metastasis. IImmunoediting was suspected to 
be the cause of acquired resistance, but no mutations 
were found in the antigen processing and presentation 
genes, eg the HLA genes, B2M, JAK1, JAK2, PTEN, or 
TAP1.49 Future molecular studies revealing the genetic 
makeup of resistant tumors are needed to elucidate why 
some Lynch syndrome tumors may not respond to 
immunotherapy.
The majority of the cases presented here were 
offered immunotherapy due to an MSI phenotype. It is 
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important to note that while dMMR is largely associated 
with MSI in Lynch syndrome colorectal (98%)50 and 
endometrial (94%)51 cancers, the concordance is much 
lower for other Lynch syndrome cancer types such as 
urothelial cancer (23%)52 and brain tumors (0%).53 In 
accordance with this, an MSS phenotype has been found 
in 36% of Lynch syndrome tumors, with associations to 
noncolorectal, nonendometrial tumors and MSH6 and 
PMS2 gene variants.54 Abida et al, presented one case 
with prostate cancer and an MSH6 germline pathogenic 
variant, but due to an MSS phenotype this patient was 
not treated.31 In contrast, Bari et al, reported one MSS 
Lynch syndrome tumor that had continued response at 
nine months, but immunohistochemical dMMR was not 
reported in this abstract.21 Though data is still scarce, it 
is possible that thorough molecular diagnostics, eg, both 
dMMR and MSI in addition to deeper analyses such as 
tumor mutation burden, may help guide treatment 
decision.21,25,31
Tumor mutation burden may add valuable knowledge 
in the selection of Lynch syndrome patients to immu-
notherapy, although this has only been investigated and 
associated with positive responses in some of the 
included case reports.29,31,32,49 Two cases with locally 
advanced rectal cancer showed high tumor mutation 
burden and experienced complete pathological 
response,29 while two of the cohort studies only asso-
ciated high tumor mutation burden with MSI status and 
did not use it as an independent indicator for treatment 
response.29,31,32 In contrast, a recent case study reported 
discrepancies between MSI and tumor mutation 
burden.55 Two Lynch syndrome cancer patients: one 
with a dMMR and MSI hepatic cholangiocarcinoma 
and one with a dMMR but MSS neuroendocrine carci-
noma were treated with nivolumab in combination with 
ipilimumab and pembrolizumab, respectively, and both 
progressed after three cycles of treatment. The authors 
suspected that the resistance was caused by lack of 
neoantigen presentation as these tumors showed low 
tumor mutation burden.55 Yet, the nonresponsive pan-
creatic cancer reported by Hu et al, presented with 
a high tumor mutation burden with massive tumor- 
infiltrating lymphocytes.49 These data emphasize the 
tumor heterogeneity and lack of solid molecular markers 
to select responsive cases. To this end, we may add that 
it is possible that MSS tumors appearing in Lynch 
syndrome cancer patients may simply not arise from 
the pathogenic germline MMR variants, and that the 
specific MMR gene mutated as well as the mutation 
type may affect cancer risk and survival.56,57 It is pos-
sible that the type of mutation may affect the tumor 
mutation burden and the number of neoantigens pre-
sented, hypothetically triggering the immune system 
differently and affect responses to treatment with 
immune checkpoint inhibitors.
Owing to scarce Lynch syndrome specific response 
data, we included case reports in our review. The major-
ity of these cases presented with positive treatment 
responses indicating publication bias. Hence, these 
results should be interpreted with caution. However, 
the summarized ORR from all the cases was 40% for 
colorectal cancer and 53% for noncolorectal cancers, 
which is in alignment with the Lynch syndrome- 
specific ORR presented in the larger cohort studies 
(ORRs between 46 and 71% for colorectal cancers and 
between 14 and 100% noncolorectal cancers). Another 
limitation to this study is the inclusion of eight indivi-
duals with VUS alterations. These individuals have pre-
viously been categorized as Lynch-like or unexplained 
MMR deficiency, as they may be caused by biallelic 
somatic MMR mutations within the tumor.58,59 Though 
these tumors may mimic Lynch syndrome tumors with 
an MSI phenotype, the colorectal cancer risk is some-
what lower compared to Lynch syndrome carriers of 
pathogenic variants.59 Specific response data were not 
reported according to MMR variants in the unselected 
cohort described by Le et al,25 but focusing on the case 
reports with VUS individuals, we observed ORRs of 0% 
and 50% for colorectal and noncolorectal cancer, 
respectively. The corresponding numbers were 17% 
and 53% for verified pathogenic MMR gene variant 
carriers.
Conclusion
Despite the fact that data is still scarce, we have found 
that Lynch syndrome cancer patients may benefit from 
immune checkpoint-based therapies and that no differ-
ence in the response rates has been reported to date 
between Lynch syndrome and sporadic MSI cancer 
patients. It remains unknown, however, why some 
Lynch syndrome cancer patients do not respond to 
immune checkpoint-based therapies and thorough mole-
cular profiling including dMMR, MSI, tumor mutation 
burden, and immunoediting driver mutations may aid in 
the selection of patients, who are more likely to 
respond. Until the routes of resistance are clarified, it 
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is encouraged to report Lynch syndrome-specific out-
come data from the large clinical trials.
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